ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2017
ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure.
Article in European heart journal supplements : journal of the European Society of Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- MiR-200a promotes the survival of cardiac cells and improves cardiac injury in chronic heart failure rats.Archives of medical science : AMS · 2025Article
- Peripartum cardiomyopathy: a comprehensive and contemporary review.Heart failure reviews · 2024Review
- The Liver in Heart Failure: From Biomarkers to Clinical Risk.International journal of molecular sciences · 2023Review
- Neurohumoral Activation in Heart Failure.International journal of molecular sciences · 2023Review
- Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure.Journal of clinical medicine · 2022Review
- Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective.Journal of clinical medicine · 2021Review
- Galectin-3 in Cardiovascular Diseases.International journal of molecular sciences · 2020Review
- miR-129-5p improves cardiac function in rats with chronic heart failure through targeting HMGB1.Mammalian genome : official journal of the International Mammalian Genome Society · 2019Article
- The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers.Current heart failure reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarkers have dramatically impacted the way heart failure (HF) patients are evaluated and managed. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacological responses to a therapeutic intervention. Natriuretic peptides [B-type natriuretic peptide (BNP) and N-terminal proBNP] are the gold standard biomarkers in determining the diagnosis and prognosis of HF, and a natriuretic peptide-guided HF management looks promising. In the last few years, an array of additional biomarkers has emerged, each reflecting different pathophysiological processes in the development and progression of HF: myocardial insult, inflammation, fibrosis, and remodelling, but their role in the clinical care of the patient is still partially defined and more studies are needed before to be well validated. Moreover, several new biomarkers have the potential to identify patients with early renal dysfunction and appear to have promise to help the management cardio-renal syndrome. With different biomarkers reflecting HF presence, the various pathways involved in its progression, as well as identifying unique treatment options for HF management, a closer cardiologist-laboratory link, with a multi-biomarker approach to the HF patient, is not far ahead, allowing the unique opportunity for specifically tailoring care to the individual pathological phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.